Status:
COMPLETED
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Lead Sponsor:
Adagene (Suzhou) Limited
Conditions:
Solid Tumor
Non-Hodgkin Lymphoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This is a Phase 1, open-label, dose-escalation, single-center study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/ refractory non-Hodgkin lymphoma. ADG106 is a fully h...
Eligibility Criteria
Inclusion
- Male or female, 18 years to 75 years of age at the time of consent.
- Provide written informed consent.
- Subjects with advanced and/or metastatic histologically or cytologically confirmed solid tumor and/or non-Hodgkin lymphoma who are refractory or relapsed from standard therapy and who have exhausted all available therapies.
- At least one measurable lesion per RECIST 1.1 for solid tumors and per Lugano Classification for non-Hodgkin lymphoma
- ECOG performance: 0-1
- Adequate organ and bone marrow function
- After receiving the last treatment (chemotherapy, radiotherapy, biotherapy or other research drugs), the patient had a washout period of at least 4 weeks or more than 5 half-lives, and had recovered from any toxic reaction of the previous treatment to less than 1 degree.
- No other concomitant antineoplastic therapy (including cell therapy)
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within the 7 days prior to study drug administration.
- Coagulation function is basically normal, INR≤1.5
- Cooperative in observation of adverse events and efficacy
Exclusion
- Subjects with positive HCV antibody，or active hepatitis B (HBV DNA ≥ 10000 copies/mL or 2000 IU/mL), or positive hepatitis virus and taking antiviral drugs
- Subjects with meningeal metastasis, or subjects with brain metastasis lesions ≥ 1 cm and untreated, or subjects with brain metastasis requiring mannitol or other dehydration therapy
- Infection of human immunodeficiency virus (HIV), or suffering from other acquired, congenital immunodeficiency disorders, or organ transplantation history
- Any active autoimmune disease or evidence-based autoimmune disease, or systemic syndrome requiring systemic steroids or immunosuppressive drugs (Except for inactive vitiligo, psoriasis, asthma/specific reactivity in children after treatment within two years, or thyroid diseases controlled by alternative therapy/non-immunosuppressive therapy）
- The residual toxicity of the patient's previous treatment was more than grade 1
- Fever body temperature above 38℃ or there are clinically obvious active infections that can affect clinical trials
- Overdose of glucocorticoid (\>10mg/d prednisone or equivalent dose) or other immunosuppressive agents was used within one month
- According to the investigator, any uncontrollable serious clinical problems include but are not limited to, evidence of severe or uncontrollable systemic diseases (such as unstable or uncompensated respiratory, cardiac, liver or kidney diseases); and any unstable systemic diseases (including active infections, refractory high or drug failure Controlled hypertension (\>150/100 mmHg), unstable angina pectoris, congestive heart failure, liver and kidney or metabolic diseases）
- A clear history of neurological or psychiatric disorders, including epilepsy or dementia
- Non-research-related surgical procedures performed prior to the use of research drugs in patients within 28 days
- Investigator do not consider he/she appropriate to participate in this study
- Pregnant or lactating women
Key Trial Info
Start Date :
December 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2021
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT03802955
Start Date
December 20 2018
End Date
November 1 2021
Last Update
April 24 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510000
2
Shanghai Dongfang Hospital
Shanghai, Shanghai Municipality, China, 200120